ESMO 2024: Optimising the personalisation of prostate cancer treatment
Professor Ellis talks to ecancertv about the upcoming Targeted Anticancer Therapies Congress (TAT 2015). He attests to the importance of the congress in aiding the intellectual development of oncologists, doctors and industry. This is especially true in the case of emerging new therapies where TAT provides a unique forum for information – both positive and negative – to be freely exchanged, cutting across different fields of basic and clinical research.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
GIST tumours and soft tissue sarcomas
Hormonal receptor positive breast cancer adjuvant and metastatic indications
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Choosing Wisely in pathology
Choosing Wisely in radiology Tanzania